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Abstract Presenilin-2 is a gene of unknown function recently 
identified based upon linkage with some forms of familial 
Alzheimer's disease. To investigate potential effects of PS-2 on 
cell viability, rat pheochromocytoma (PC12) cells were stably 
transfected with cDNA constructs encoding either full-length 
human PS-2 or, for comparison, mouse Bcl-xL. Overexpression 
of PS-2 conferred increased sensitivity to the apoptotic stimuli 
staurosporine and hydrogen peroxide. In contrast, Bcl-XL 
overexpression significantly reduced cell death induced by these 
stimuli. These results suggest that one function of PS-2 may 
involve modulation of cell viability. 
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T cell hybridoma transfected with ALG-3, a partial cDNA 
that appears to be the mouse homologue of PS-2, exhibits 
decreased vulnerability to T cell receptor- and Fas-induced 
apoptosis [12]. Unclear, however, is whether the cell death 
resistance conferred by the truncated PS-2 homologue repre- 
sents dominant negative inhibition of full-length PS-2 and or 
direct anti-apoptotic activity of a putatively translated ALG-3 
polypeptide. To examine further the potential actions of PS-2 
gene in regulation of cell viability, we stably transfected PC12 
cells with a full-length uman PS-2 cDNA construct and com- 
pared its effects on cell viability relative to wild type PC12 
cells and those transfected with either empty vector or the 
anti-apoptotic gene Bcl-xL. 
2. Materials and methods 
1. Introduction 
The presenilin-2 (PS-2/STM2) gene was recently identified 
as the chromosome 1 locus of missense mutations linked to 
familial Alzheimer's disease (AD) within specific kindreds 
[1,2]. Although the etiology of AD is unknown, elucidating 
the contributions of genes linked to the disease promises to 
provide insight into relevant pathological pathways. In addi- 
tion to PS-2, genes implicated in AD pathogenesis include 
allelic variation of apolipoprotein E on chromosome 19 [3,4] 
as well as mutations of amyloid precursor protein gene (APP) 
on chromosome 21 [5-7] and presenilin 1 (PS1/S182) on chro- 
mosome 14 [8]. Although cellular roles of apolipoprotein E
and APP have been reported, the normal function(s) of the 
related PS-2 and PS-1 genes has not been determined. 
Recently, it has been suggested that presenilins may play a 
role in protein processing and trafficking since mutations in 
both PS-1 and PS-2 alter APP processing [9]. Another poten- 
tial functional role of PS-2 that may be consistent with its AD 
association is modulation of apoptotic cell death. Apoptosis 
or programmed cell death is an efficient mechanism for cellu- 
lar removal that is associated with both the normal develop- 
ment and maintenance of many tissues, including brain [10]. 
We have proposed that apoptotic pathways also may contrib- 
ute to pathological cell death in chronic neurodegenerative 
diseases such as AD [11]. Recently, it was reported that a 
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2.1. cDNA cloning and stable transfection 
To obtain a human PS-2 cDNA, a 1 ~1 aliquot from the human 
brain cDNA library (Stratagene) was amplified by polymerase chain 
reaction (PCR) with the following primers [1]: forward GCCAA- 
GAATTCGTGGTGCTTCCAGAGGCA (containing the EcoRI re- 
striction site) and reverse GCAGCTCTAGAAAATTCCCTGCAGC- 
TTGCA (containing the XbaI restriction site). To obtain full length 
Bcl-xc cDNA [13], first strand cDNA synthesized from mouse brain 
mRNA using a cDNA cyclic kit (Invitrogen) was amplified by PCR 
with following primers: forward TGGCTCTAGAGACCTTCCGGG- 
GGTTGTACC (containing XbaI restriction site) and reverse 
TGGCTCTAGACAGTGTCTGGTCACTTCCGA (containing XbaI 
restriction site). PCR was performed under the following conditions: 
94°C, l min; 60°C, 1 min; and 72°C, 2 rain (PS-2) or 1 min (Bcl-xL) 
for 30 cycles. PCR products were digested by corresponding restric- 
tion enzymes and ligated to a pcDNA3 vector (Invitrogene). The 
orientation and sequences of positive inserts were verified using se- 
quenase 2 on double strands. PC12 cells were transfected by electro- 
poration (Electro Cell Manipulator ECM 100, BTX) with the 
pcDNA3 plasmid containing either human PS-2 or mouse Bcl-xe un- 
der CMV promoter. As a control, transfections were also performed 
with the pcDNA3 plasmid without an insert. After G418 (800/ag/ml) 
selection for 2 weeks, colonies were randomly selected by limited 
dilution. 
2.2. RNA extraction and Northern blot analysis 
Total RNA was isolated from the different colonies by the guani- 
dine thiocyanate method [14]. 10-I, tg aliquots of total RNA were de- 
natured in 2.2 M formaldehyde at 65°C for 15 min and electrophor- 
esed on 1.2% agarose/2.2 M formaldehyde gels at 50 V for 4 h. The 
separated RNA was transferred to nylon membrane by the overnight 
capillary blotting method in 6 x SSC buffer and immobilized by UV 
irradiation. Hybridization was performed with [32p]dCTP-labeled hu- 
man PS2 and mouse Bcl-xL cDNA fragment in a solution containing 
5 X SSPE, 5 × Denhardt's, and 1% SDS at 65°C overnight. The blots 
were washed twice in 2 x SSPE/0.5% SDS, 0.5 x SSPE/0.5%SDS and 
0.2XSSPE/0.5%SDS solution at 65°C, 15 min each and then were 
exposed to film at -80°C for 3-5 days. 
2.3. Cytotoxieity assays 
To assess cell survival, WT and transfected PC12 cells were plated 
on poly(L-lysine)-coated multiwell plates at 1 X 104 cells/cm 2 in Dul- 
becco's modified Eagle's medium (DMEM) medium containing 10% 
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Fig. 1. Expression of Bcl-xL and PS-2 mRNA in transfected and wild type PC12 cells. 10 gg of total RNA isolated from the indicated clones 
was separated on 1.2% agarose/formaldehyde gels. Northern blot analysis was carried out with either a 0.9 kb mouse Bcl-xL or a 1.4 kb human 
PS-2 probe. (A) Expression of Bcl-xL mRNA. An approx. 2.4 kb endogenous transcript appeared in PC12 wild type (PCI2WT), empty vector 
(pcDNA-Neo) and Bcl-xL (pcDNA-Bcl-xL) transfectants. A major Bcl-xL band was expressed in pcDNA-Bcl-xL. (B) Expression of PS-2 
mRNA. An approx. 2.5 kb endogenous transcript was found in all clones. Human PS-2 transfectant (pcDNA-PS2 expressed two more bands 
derived from pcDNA-PS2 vector. 
fetal bovine serum (FBS). After 1 day in vitro, cultures were shifted to 
DMEM/I% FBS for 1 day and then to serum-free DMEM containing 
different levels of staurosporine and hydrogen peroxide for 18-24 h. 
Over the 18-24 h experimentation period, the absence of serum did 
not result in significant cell loss. Cell viability was quantitatively as- 
sessed by spectrophotometric measurement of MTT reduction [15]. 
These data were verified by morphological evaluation under bright- 
field and phase contract optics and by nuclear examination under 
fluorescent illumination following addition of the nucleic acid stain 
Syto-ll (Molecular Probes). All conditions were performed in tripli- 
cate wells and were repeated in at least 3 independent experiments 
with similar findings. To permit comparisons between cell lines, raw 
MTT data were normalized to percentage values of untreated controls 
and statistically examined using ANOVA followed by Fisher LSD 
test. For graphical presentation, data from single, representative ex- 
periments are shown. 
3. Results 
3.1. Transfi,cted PC12 cells express human PS-2 and mouse 
Bcl-XL RNAs 
PCI2 cells were transfected with either empty vector 
(pcDNA-Neo),  human PS-2 gene (pcDNA-PS2) or mouse 
Bcl-xL (pcDNA-Bcl-xL) and stable transfectants were selected 
by G418 exposure. Successful expression of PS-2 and Bcl-xL 
constructs was confirmed by Northern blot analysis (Fig. 1). 
Northern Nots revealed that WT and pcDNA-Neo cells have 
low endogenous levels of PS-2 expression with an approx. 2.5 
kb transcript. In addition, pcDNA-PS2 cells exhibit one major 
transcript corresponding to the coding region (~ 1.4 kb) and 
Fig. 2. Nuclear staining with the dye Sytool 1 viewed under fluores- 
cent illumination shows pyknotic nuclei (arrows), a characteristic of
apoptosis, in PC12 WT cultures treated with 4 nM staurosporine 
(B) and 100 gM hydrogen peroxide (C) but not in untreated con- 
trols (A). For clarity, figure shows negative images. 
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Fig. 3. Microscopic inspection of cultures shows that staurosporine toxicity is potentiated in PS-2 transfected cells but attenuated in Bcl-XL 
transfected cells: (A) untreated pcDNA-Neo cells, (B) pcDNA-Neo cells treated with 4 nM staurosporine, (C) pcDNA-PS2 cells treated with 
4 nM staurosporine, (D) pcDNA-Bcl-XL cells treated with 4 nM staurosporine. Viable cells are darkly stained with blue formazan product fol- 
lowing 1 h exposure to MTT reagent [15], as viewed under bright-field microscopy. Scale bar, 100 Ittm. 
one minor transcript probably corresponding to vector (Fig. 
1A). In pcDNA-Bcl-XL cells, high levels of a major Bcl-xL 
transcript (=  1 kb) were detected as well as an endogenous 
transcript (=  2.5kb) (Fig. 1B). 
3.2. Overexpression of human PS-2 gene increases vulnerability 
to staurosporine toxicity 
To investigate whether PS-2 may modulate cellular sensitiv- 
ity to degeneration, cultures were examined following expo- 
sure to the apoptotic insults staurosporine [16,17] and hydro- 
gen peroxide [18]. In the absence of cellular insults, neither 
pcDNA-PS2 nor the other PC12 lines exhibited significant 
spontaneous degeneration over the course of experimentation 
(data not shown). However, in all PCl2 lines 18-24 h expo- 
sure to 1-10 nM staurosporine induced cell death with mor- 
phological features indicative of apoptosis (Fig. 2B), a finding 
consistent with reports of staurosporine toxicity in other cell 
systems [16,17]. Significantly, the four cell lines showed differ- 
ent responses to staurosporine. Specifically, the pcDNA-PS2 
line exhibited increased sensitivity to staurosporine toxicity 
relative to the WT and pcDNA-Neo lines, as assessed by 
visual inspection (Fig. 3); this effect did not appear to be 
time-dependent (data not shown). The observed potentiation 
of staurosporine toxicity in PS-2 transfectants was quantified 
using the MTT reduction assay. For example, as shown in 
Fig, 4A, following 4 nM staurosporine treatment WT and 
pcDNA-Neo lines exhibited 46.5 + 1.1 and 44.6 + 0.1% viabil- 
ity, respectively, whereas the pcDNA-PS2 line retained only 
17.8 + 1.4% viability. In contrast o the significant potentia- 
tion of cell death observed in the pcDNA-PS2 cells, the 
pcDNA-Bcl-xL line exhibited robust protection against stau- 
rosporine-induced toxicity (Figs. 3D and 4A). 
3.3. Overexpression of human PS-2 gene increases vulnerability 
to hydrogen peroxide 
To determine if the enhanced vulnerability of pcDNA-PS2 
cells to staurosporine toxicity extrapolates to other types of 
insults, PC12 cell lines were exposed to the pro-oxidant hy- 
drogen peroxide. Exposure of PC12 cells to hydrogen perox- 
ide for 18-24 h caused a dose-dependent reduction in cell 
viability that exhibited classic features of apoptosis, including 
apoptotic bodies and pyknotic nuclei (Fig. 2C). In close agree- 
ment with the staurosporine data, we found that PS-2 over- 
expression potentiated hydrogen peroxide toxicity, whereas 
Bcl-xL overexpression provided partial protection to PC12 
cells (Figs. 3 and 4B). 
4. Discussion 
Identification of PS-2 as a locus for mutations linked to 
specific forms of early-onset familial AD has generated sig- 
nificant interest in determination of the gene's normal func- 
tional role(s) and, subsequently, how their alteration by mis- 
sense mutations contributes to the disease process. In this 
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Fig. 4. Quantitative analysis of cell viability regulation by PS-2 and 
Bcl-XL overexpression following exposure to various doses of stauro- 
sporine (A) and hydrogen peroxide (B). Cell lines are represented 
as follows: (D) PCI2 WT; (O) pcDNA-Neo; (A) pcDNA-PS-2; 
(0) pcDNA-Bcl-XL. Data show mean values (_+ S.E.M.) normalized 
to MTT values from respective untreated controls in single, repre- 
sentative xperiments. *P< 0.05, and **P< 0.01 relative to matched 
values from WT condition. 
report, we have demonstrated that PC12 cells stably trans- 
fected with full-length human PS-2 exhibit significantly in- 
creased sensitivity to cell death induced by the apoptotic in- 
suits staurosporine and hydrogen peroxide, suggesting that 
one role of PS-2 involves regulation of cell viability. 
The proposed role of PS-2 in the cellular regulation of 
apoptosis is consistent with findings mentioned above that a 
truncated murine homologue of PS-2 called ALG-3 can rescue 
a T cell hybridoma from apoptotic insults [12]. One possible 
mechanism of ALG-3 protection that is consistent with our 
current results is that ALG-3 may function as an inhibitor of 
PS-2. If this hypothesis i correct, the pro-apoptotic function 
of PS-2 may be opposed by ALG-3. Thus, a proper balance 
between PS2 and its putative truncated protein may be crucial 
to regulation of cell viability. Although the functional rela- 
tionship of PS-2 to familial AD is unknown, one might an- 
ticipate disruption of this balance in favor of increased apop- 
tosis as a result of mutation-mediated alterations in the 
processing or activity of PS-2. 
The theory that PS-2 function is characterized by an in- 
creased sensitivity to apoptotic insults is consistent with 
pathological mechanisms thought to underlie neuronal oss 
in AD. Both in vitro [18-21] and in vivo [22,23] data show 
that cellular insults (e.g. fibriUar ~-amyloid, oxidative stress) 
implicated as causal agents in AD neurodegeneration nduce 
apoptosis. Recent histochemical evidence in AD brain tissues 
demonstrates several morphological features consistent with 
apoptosis, including chromatin condensation and nuclear 
fragmentation as well as the induction of genes related to 
apoptosis and cell death [24-27]. It appears, however, that 
the AD brain displays a complex expression pattern of gene 
products regulating cell death, including those in the Bcl fam- 
ily [27], suggesting competing pro- and anti-apoptotic mech- 
anisms. For example, many neurons that show DNA damage 
also exhibit increased levels of Bcl-2 [27]. Another member 
of the Bcl family likely to be important in regulating cell 
viability in brain is Bcl-XL, which maintains high levels in 
neurons throughout life. Our culture findings suggest hat 
Bcl-XL enhances cell survival whereas PS-2 may be involved 
in promoting cell death. 
In addition to the present data suggesting a modulatory 
role of PS-2 in cell viability, other evidence suggests possible 
roles in protein trafficking and signal transduction. For exam- 
ple, the amino acid sequence of PS-2 predicts an integral 
membrane protein with seven transmembrane domains. Par- 
tial amino acid sequence homology between PS-2 and the C. 
elegans genes SPE-4 [28] and SEL-12 [29] supports the hy- 
pothesis that PS-2 may have a role in protein trafficking or 
signal transduction. Finally, it has been reported recently that 
AD-linked mutations in PS-2 cause altered processing of the 
APP protein yielding increased production of the particularly 
amyloidogenic X-42/43 forms of [3-amyloid [9]. 
The hypothesized involvement of PS-2 in both protein traf- 
ficking and cell death regulation eed not be mutually exclu- 
sive roles. For example, activation of a single PS-2 intracel- 
lular pathway potentially may produce multiple cellular 
consequences, including those contributing to modulation of 
cell viability (e.g. calcium regulation) and protein trafficking 
or processing. One could speculate that AD-linked PS-2 mu- 
tations may cause disruption of such a pathway, altering func- 
tionality of relevant PS-2 cellular roles. Thus, PS-2 mutations 
may result in not only increased production of deleterious X- 
42/43 13-amyloid but perhaps also enhanced sensitivity to 
apoptotic stimuli (e.g. 13-amyloid). The co-occurrence of 
both pathological pathways would be predicted to interact 
synergistically, perhaps explaining why familial AD associated 
with presenilin mutations exhibit a particularly early onset 
and a relatively high prevalence. Examination of these issues 
will require study of how AD-linked presenilin mutations af- 
fect normal functions in vitro and in vivo. 
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